Baillie Gifford & CO Procept Bio Robotics Corp Transaction History
Baillie Gifford & CO
- $128 Billion
- Q2 2025
A detailed history of Baillie Gifford & CO transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Baillie Gifford & CO holds 876,363 shares of PRCT stock, worth $33.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
876,363
Previous 313,884
179.2%
Holding current value
$33.8 Million
Previous $18.3 Million
176.05%
% of portfolio
0.04%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding PRCT
# of Institutions
292Shares Held
44MCall Options Held
248KPut Options Held
90.9K-
Vanguard Group Inc Valley Forge, PA5.25MShares$203 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$135 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY2.16MShares$83.3 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.53MShares$59 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.32MShares$51 Million0.01% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $1.72B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...